Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:47p EARNINGS REVIEW AND FREE RESEARCH RE : Johnson & Johnson’s Adjusted EPS Gr..
01:47p JOHNSON & JOHNSON : Earnings Review and Free Research Report: Johnson & Johnson..
07/19 JOHNSON & JOHNSON : UNFPA Support Training of Midwives As Master Mentors Ends in..
07/19 JOHNSON & JOHNSON : Today's Research Reports on Stocks to Watch: Johnson & Johns..
07/19DJJOHNSON & JOHNSON : J&J Expects Drug Sales to Pick Up -- WSJ
07/19 JOHNSON & JOHNSON : U.S. homebuilder sentiment down in July
07/18 CUTERA : Global Acne Treatment Market 2017 Analysis, by Players - Galderma, Veri..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : ups expectations
More news
News from SeekingAlpha
07:55a Premarket analyst action - healthcare
07/19 How Safe Are The Dividends Of These Stalwarts?
07/19 Johnson & Johnson's Weakness Worries Me
07/19 JOHNSON & JOHNSON : This Market Will Buy Anything
07/19 Immunogen Finally Moving 'FORWARD'?
Financials ($)
Sales 2017 75 820 M
EBIT 2017 22 896 M
Net income 2017 16 676 M
Debt 2017 6 183 M
Yield 2017 2,48%
P/E ratio 2017 22,22
P/E ratio 2018 18,30
EV / Sales 2017 4,89x
EV / Sales 2018 4,52x
Capitalization 364 233 M
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 138 $
Spread / Average Target 2,0%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.36%364 233
NOVARTIS8.64%222 570
ROCHE HOLDING LTD.4.56%220 588
PFIZER3.51%200 211
MERCK AND COMPANY6.37%171 276
SANOFI6.94%119 307